Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

SKYE US Equity

Skye Bioscience, Inc.Health Care · Pharmaceutical Preparations · CIK 1516551 · FY ends Dec 31
$0.36
-0.06 (-13.51%)
USD · as of 2026-08-18 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-10in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · For a description of material legal proceedings, see Note 12 to the accompanying consolidated financial statements.

Item 9A · ICFR · Based on their assessment, our management concluded that, as of December 31, 2025, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.

2024-12-312025-03-20in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · For a description of material legal proceedings, see Note 11 to the accompanying consolidated financial statements.

Item 9A · ICFR · Based on their assessment, our management concluded that, as of December 31, 2024, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.

2023-12-312024-03-22in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · See Note 13 to the accompanying consolidated financial statements included in Part IV, Item 15 of this Annual Report on Form 10-K.

Item 9A · ICFR · Based on their assessment, our management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.

2022-12-312023-03-31described hereeffectiveeffectivenone in Item 9AEDGAR

Item 3 · Cunning Lawsuit The Company is a party to a legal proceeding with a former employee alleging, among other things, wrongful termination, violation of whistleblower protections under the Sarbanes-Oxley Act of 2002 and retaliation under California law against the Company relating to certain actions and events that occurred with the Company's former management during the employee's employment term from March 2018 to July 2019. The case, entitled Wendy Cunning vs Skye Bioscience, Inc., was filed in U.S. District Court for the Central District of California (the "Cunning Lawsuit"). On January 18, 2023, a jury rendered a verdict in favor of Ms. Cunning and awarded her $512,500 in economic damages (e.g., lost earnings, future earnings and interest), $840,960 in non-economic damages (e.g., emotional distress) and $3,500,000 in punitive damages. The plaintiff's counsel has also filed a motion for attorney fees claiming fees of $1,351,850 and a multiplier of 1.5, for a total of $2,042,775. The Company strongly believes that this case was incorrectly decided as to liability, the amount of compensatory damages, and the appropriateness and amount of punitive damages. The Company intends to vigor…

Item 9A · ICFR · Based on their assessment, our management concluded that, as of December 31, 2022, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.

2021-12-312022-03-28described hereeffectiveeffectivenone in Item 9AEDGAR

Item 3 · On June 3, 2021, Wendy Cunning, a former employee of the Company, initiated a legal proceeding against the Company in the U.S. District Court Central District of California (the "Action"). The Action asserts claims by Ms. Cunning for violation of whistleblower protections under the Sarbanes-Oxley Act, retaliation under California labor code section 1102.5, wrongful termination in violation of public policy and intentional infliction of emotional distress, against the Company. The Action seeks monetary damages in an indeterminable amount and civil penalties. The Company denies all claims and is vigorously defending the Action.

Item 9A · ICFR · Based on their assessment, our management concluded that, as of December 31, 2021, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.